Catalogo dei prodotti della ricerca

RUGGIERI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.680
EU - Europa 912
AS - Asia 569
AF - Africa 23
SA - Sud America 12
OC - Oceania 2
Totale 4.198
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.653
IT - Italia 455
SG - Singapore 203
SE - Svezia 160
IN - India 142
CN - Cina 137
DE - Germania 54
FI - Finlandia 44
ID - Indonesia 44
NL - Olanda 29
CA - Canada 25
BG - Bulgaria 24
GB - Regno Unito 23
IE - Irlanda 21
RU - Federazione Russa 20
RO - Romania 18
UA - Ucraina 17
HK - Hong Kong 12
BE - Belgio 9
AR - Argentina 8
FR - Francia 8
TR - Turchia 8
CZ - Repubblica Ceca 7
ES - Italia 7
TG - Togo 7
EG - Egitto 6
IL - Israele 6
MA - Marocco 5
ZA - Sudafrica 4
BR - Brasile 3
RS - Serbia 3
BD - Bangladesh 2
BY - Bielorussia 2
DK - Danimarca 2
GR - Grecia 2
IQ - Iraq 2
IR - Iran 2
KR - Corea 2
LB - Libano 2
MX - Messico 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BO - Bolivia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
KZ - Kazakistan 1
LT - Lituania 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
SY - Repubblica araba siriana 1
Totale 4.198
Salva come PNG Salva come JPEG
Città #
Fairfield 457
Ashburn 236
Woodbridge 201
Chandler 186
Seattle 154
Rome 151
Singapore 151
Cambridge 145
Wilmington 144
Houston 142
Princeton 86
San Paolo di Civitate 86
Beijing 71
Santa Clara 64
Ann Arbor 57
San Diego 56
Lawrence 53
Jakarta 43
Boston 41
Millbury 41
Plano 36
Norwalk 32
Sofia 24
Helsinki 20
Milan 19
Dublin 17
Munich 14
Naples 14
New York 14
Ottawa 12
Andover 11
Dearborn 11
Fasano 11
San Mateo 11
Boardman 10
Enschede 10
Hong Kong 10
Moscow 10
Toronto 10
Brussels 9
Federal 8
Florence 8
Falkenstein 7
Lomé 7
Washington 7
Amsterdam 6
Bühl 6
London 6
Des Moines 5
Kunming 5
Los Angeles 5
Phoenix 5
Ankara 4
Falls Church 4
Hebei 4
Palermo 4
Paris 4
Pescara 4
Pune 4
Redwood City 4
Stockholm 4
Belgrade 3
Bilbao 3
Bologna 3
Bonndorf 3
Capannori 3
Ealing 3
Fremont 3
Lappeenranta 3
Liverpool 3
Livorno 3
Mestre 3
Muizenberg 3
Nuremberg 3
Pesaro 3
Prato 3
Sacramento 3
Tappahannock 3
Baqubah 2
Bari 2
Belkuchi 2
Belo Horizonte 2
Brno 2
Buffalo 2
Cercola 2
Cosenza 2
Dallas 2
Grottaglie 2
Guangzhou 2
Hangzhou 2
Heraklion 2
Hyderabad 2
Istanbul 2
Jiaxing 2
Jinan 2
Latina 2
Laurel 2
Madrid 2
Mannheim 2
Mexico City 2
Totale 3.076
Salva come PNG Salva come JPEG
Nome #
Listeria monocytogenes-Induced rhombencephalitis in a patient with multiple sclerosis treated with dimethyl fumarate 105
CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis 96
CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. 91
Dysregulated homeostasis of acetylcholine levels in immune cells of RR-multiple sclerosis patients 90
Association of deep gray matter damage with cortical and spinal cord degeneration in primary progressive multiple sclerosis 89
Cesarean section in women with MS: A choice or a need? 88
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 84
Cesarean section in women with MS: a choice or a need? 83
Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: Implication in peripheral inflammation 81
Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis 80
CD28 individual signals amplify pro-inflammatory cytokine production in relapse-remitting multiple sclerosis T lymphocytes. 80
T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis 80
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 79
Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients 79
The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS 77
FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis 75
Efficacy and safety of laquinimod in multiple sclerosis: Current status 73
Fingolimod vs dimethyl fumarate in multiple sclerosis. a real-world propensity score-matched study 73
Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach 71
Modulation of P2X7 receptor during inflammation in multiple sclerosis 71
Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study 71
A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis 71
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis 69
FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients 68
Relation between functional connectivity and disability in multiple sclerosis. a non-linear model 68
Lesion symptom map of cognitive–postural interference in multiple sclerosis 67
Premorbid functional reserve modulates the effect of rehabilitation in multiple sclerosis 67
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies 67
New oral drugs for multiple sclerosis 66
A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis 65
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 64
‘Posture second’ strategy predicts disability progression in multiple sclerosis 60
null 59
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study 59
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 59
Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction 57
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis 55
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration 55
Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis 54
Progression of regional grey matter atrophy in multiple sclerosis 53
EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS 53
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies 51
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study 50
Multi-scale resting state functional reorganization in response to multiple sclerosis damage 50
Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort 50
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy 49
Mathematical modelling characterises fatigability as a distinct phenomenon in patients with multiple sclerosis 49
Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references 49
Advances in spinal cord imaging in multiple sclerosis 48
Deep gray matter volume loss drives disability worsening in multiple sclerosis 47
null 46
Emerging oral drugs for relapsingremitting multiple sclerosis 46
Advances in the treatment of relapsing-remitting multiple sclerosis - Critical appraisal of fingolimod 43
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies 43
Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm 41
Consensus Paper: Ataxic Gait 39
Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis 38
Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study 38
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience 36
Listeria Monocytogenes-Induced Rhombencephalitis-A Paradoxical Disease of Immunocompetent Patients-Reply 35
Eating Hubs in Multiple Sclerosis: Exploring the Relationship Between Mediterranean Diet and Disability Status in Italy 34
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag. 2013;9:73-85. doi: 10.2147/TCRM.S17426. Epub 2013 Mar 3. 34
null 33
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis 33
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis 32
Lifespan normative data on rates of brain volume changes 32
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies 32
MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis 32
Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques 30
Tumefactive Demyelinating Lesions and Pregnancy 30
The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease 30
Should we treat pediatric radiologically isolated syndrome? An 18-year follow-up case report 29
Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis 29
Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis 29
Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study 29
Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative 28
null 27
A matter of atrophy: differential impact of brain and spine volume loss on disability worsening in MS 27
Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability 26
Potential rotective role of pregnancy and breastfeeding in delaying onset symptoms related to multiple sclerosis 25
Shift of multiple sclerosis onset towards older age 25
null 24
Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis 24
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets 22
Evaluation of drivers of treatment switch in relapsing multiple sclerosis. A study from the Italian MS Registry 21
Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis 21
Correction to: Consensus Paper: Ataxic Gait 15
Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data 14
Proinflammatory mucosal-associated invariant CD8+ T cells react to gut flora yeasts and infiltrate multiple sclerosis brain 14
The added value of spinal cord lesions to disability accrual in multiple sclerosis 9
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis 8
Totale 4.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.650
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.650
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020571 0 0 0 0 0 82 102 86 80 75 46 100
2020/2021529 20 65 18 8 27 14 149 68 30 41 24 65
2021/2022951 12 38 68 34 133 99 37 69 62 87 183 129
2022/2023831 166 184 45 61 101 65 25 39 74 18 44 9
2023/2024565 25 74 23 40 46 67 41 53 10 68 63 55
2024/2025432 43 24 69 104 106 86 0 0 0 0 0 0
Totale 4.598